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Background: Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is the most common type of
neuroendocrine tumors accounting for 65–75% of neuroendocrine neoplasms (NENs). Given the fact that there are
few studies on GEP-NENs among Chinese patients, we performed a retrospective study in South China.
Methods: Totally 178 patients with GEP-NENs treated at the First Affiliated Hospital of Sun Yat-sen University
between January 1995 and May 2012 were analyzed retrospectively.
Results: Pancreas was found the most common site of involvement (34.8%). 149 patients (83.7%) presented as
non-functional tumors with non-specific symptoms such as abdominal pain (33.7%); carcinoid syndrome was not
found in this study. Several methods are useful for localization of GEP-NENs, yielding varied detection rates from
77.8% to 98.7%. Positive rates of chromogranin A (CgA) and synaptophysin (Syn) immunhistochemically were 69.1%
and 90.2%, respectively. 87 patients (51.5%) had G1 tumors, 31(18.3%) G2 tumors and 51 (30.2%) G3 tumors.
Neuroendocrine tumor (NET), neuroendocrine carcinoma (NEC) and mixed adenoendocrine carcinoma (MANEC)
were 69.8%, 27.2% and 3.0%, respectively. 28.1% of patients presented with distant disease. Surgery was performed
in 152 (85.4%) patients, and overall 5-year survival rate was 54.5%. Functionality, G1 grading and NET classification
were associated with favorable prognosis in univariate analysis. Distant metastasis contributed to unfavorable
prognosis of these tumors.
Conclusions: Nonfunctional tumors with non-specific symptoms account for the majority of GEP-NENs. Diagnosis
depends on pathological classification. Multidisciplinary treatments could help improve the outcome.
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Neuroendocrine neoplasms, which originate from neu-
roendocrine cells distributed throughout the body, com-
prise a heterogeneous family with a wide and complex
clinical behaviors [1]. The incidence of NENs ranges
from 2.5 to 5 cases per 100,000 in the United States, and
the gastrointestinal tract is the most commonly affected
site [2,3]. According to an analysis of the National* Correspondence: chenminhu@vip.163.com; chenjie7209@yahoo.com
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reproduction in any medium, provided the orCancer Institute’s Surveillance, Epidemiology and End
Results database (SEER, http://seer.cancer.gov/data/index.
html), which is the largest epidemiologic series nowadays,
the incidence of NENs has been rising substantially in
the past 30 years.
NENs have been the subject of debate regarding opti-
mal nomenclature, grading, staging and classification of
these tumors for many years. A uniform World Health
Organization (WHO) classification greatly facilitates the
comparison of clinical, pathological and prognostic fea-
tures and results of treatment in GEP-NENs, and so do
the China Consensus Guidelines for the standards of
histopathologic diagnosis as well [4,5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of Caucasians have been well studied in western coun-
tries such as United States, Norway, Spain, German and
the United Kingdom [2,3,6-9]. But for Asian popula-
tion [10-13], especially for Chinese population, available
information on these cancers is rather limited [14].
Therefore, it requires detailed data for comprehensive
knowledge of NENs in China. Based on the 17-year data
of our hospital, a comprehensive retrospective study was
performed to examine the relationship between clinical
pathological characteristic and survival of GEP-NENs.
To our knowledge, it is the first study providing informa-
tion on these tumors using the latest histopathologic
diagnosis consensus from an Asian country.
Methods
178 patients with histologically confirmed sporadic
GEP-NENs from The First Affiliated Hospital, Sun
Yat-sen University (1995–2012) were enrolled in this
study to collect clinical information including age,
gender, locations, clinical syndromes, endoscopic and
radiographic features, histopathological characteristics,
metastasis patterns, treatment modalities and outcomes.
The histology of each patient was reviewed according
to the WHO classification [4] and China Consensus
Guidelines [5]: First, immunohistochemical staining of
CgA and Syn, which are all neuroendocrine markers,
were performed to recognize the histological patterns of
these tumors. Specific peptide hormones (eg. insulin,
glucagon and somatostatin) staining methods were not
regularly used only when a functional neuroendocrine
neoplasm was considered. Second, the Ki-67 index
(≤2%, 3–20%, and >20% per 500–2000 tumor cells in
the most active regions or hot spots, respectively) or
mitotic rate (1, 2–20, and >20 mitoses per 10 high-power
field in the most active regions or hot spots, respectively),
which was re-stained or recounted, was used to estimate
the tumor proliferative activities. Tumors with a Ki-67
index of <2% were classified as G1 tumors, index of
3–20% were classified as G2, greater than 20% as G3.
Likewise, tumors with mitotic rates of <2/10 HPF were
classified as G1, those of 2 to 20/10 HPF were classified
as G2, greater than 20/10 HPF as G3. Once the grading
of Ki-67 index disaccorded with the mitotic rate, the
higher one was preferred. Thus, GEP-NENs were classi-
fied as NET (G1 and G2), NEC (G3) and MANEC (G3).
Overall survival was defined as the time from diagnosis
to death or last follow-up in living patients. Survival rate
was estimated according to the Kaplan–Meier product
limit method, and differences between subgroups were
assessed by the log-rank test with P < 0.05 as statistically
significant. SPSS 16.0 was used for statistical analysis.
The study was approved by the ethics committee of




Among the 178 Chinese patients with GEP-NENs, 108
(60.7%) were men and 70 (39.3%) were women; male-
to-female ratio was 1.54. The mean age was 50.96 ±
15.01 years. The most common sites were the pancreas
(62/178, 34.8%), followed by rectum (36/178, 20.2%),
stomach (25/178, 14.0%), duodenum (13/178, 7.3%), meta-
static NENs of unknown primary (12/178, 6.7%) and
esophagus (7/178, 3.9%). Other sites included appendix,
jejunum/ileum, Vater’s ampulla at 12.9% (23/178). Non-
functional tumors comprised the majority of GEP-NENs
(149/178, 83.7%), whereas functional tumors accounted
for the other 16.3%. A variety of gastrointestinal manifes-
tations were caused by the effect of local compression on
nearby tissues in nonfunctional tumors. The most com-
mon initial presentation was abdominal pain (60/178,
33.7%), which was not specific for the diagnosis of tumor.
Other non-specific symptoms were gastrointestinal
bleeding (29/178, 16.3%), jaundice (16/178, 9.0%), pro-
gressive dysphagia (9/178, 5.1%), diarrhea (8/178, 4.5%),
abdominal distension (6/178, 3.4%) and so on. Incidental
diagnosis occurred in 10.1% of cases which were usually
asymptomatic. Insulinoma comprised 93.1% of functional
tumors, which mainly occurred in pancreas, occasionally
followed by the substantially rarer glucagonoma and
vasoactive intestinal peptidoma (only 1 case respectively
in our study). Typical symptoms included hypoglycemia,
epileptic seizure and secondary diabetes mellitus, which
heralded functional NENs, but carcinoid syndrome did
not present in our study. The demographics and present-
ing symptoms of GEP-NENs are listed in Table 1.
Imaging studies
The most frequently used examination procedures in-
cluded endoscopy, ultrasound, endoscopic ultrasonography
(EUS), computed tomography (CT) scan, magnatic res-
onance imaging (MRI), and positron emission computed
tomography imaging (PET-CT, using with 16 F-FDG).
Endoscopy provided the highest detection rate of 98.7%
(74/75). EUS was performed on 37 patients, of which a
lesion was found in 34 patients, promised a detection rate
of 91.9%. MRI and PET-CT, was performed in only about
10% of patients, respectively. Tumors usually appeared
as polypoid prominences, ulcer type or cauliflower-like
neoplasm under endoscopy; whereas on CT scan, they
appeared as local space-occupying lesions which were
significantly enhanced by iodinated contrast. Ultra-
sound and EUS usually demonstrated the tumors as
rounded, homogeneous, hypoechoic, well-defined and
well-vascularized masses (Table 2).
Table 1 Characteristics of study population (N = 178 patients)




Clinical symptoms Main signs
N %
Pancreas 62 34.8 32(51.6) 30(48.4) Abdominal pain, Jaundice, Hypoglycaemia Jaundice
Rectum 36 20.2 29(80.6) 7(19.4) Gastrointestinal bleeding, Abdominal pain, Diarrhea Rectum mass
Somach 25 14.0 16(64.0) 9(36.0) Abdominal pain, Gastrointestinal bleeding, Dysphagia Abdominal tenderness
Duodenum 13 7.3 10(76.9) 3(23.1) Abdominal pain, Jaundice, Gastrointestinal bleeding Jaundice
Metastasis of
unknown primary
12 6.7 6(50.0) 6(50.0) Abdominal pain, Asymptomatic, Fatigue Hepatomegaly
Esophagus 7 3.9 5(71.4) 2(28.6) Progressive dysphagia No signs
Appendix 6 3.4 2(33.3) 4(66.7) Abdominal pain, Abdominal distension Rebound pain in the
Mcburney’s point
Jejunum/ileum 4 2.2 3(75.0) 1(25.0) Gastrointestinal bleeding, Small bowel obstruction Anemia
Gallbladder 4 2.2 1(25.0) 3(75.0) Jaundice, Asymptomatic Jaundice
Vater’s ampulla 3 1.7 3(100) 0(0) Jaundice, Abdominal pain, Jaundice
Peritoneum 3 1.7 0(0) 3(100) Abdominal pain, Asymptomatic Abdominal mass
Cecum 1 0.6 1(100) 0(0) Abdominal pain Abdominal mass
Choledoch 1 0.6 1(100) 0(0) Jaundice Jaundice
Greater omentum 1 0.6 0(0) 1(100) Asymptomatic No signs
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Overall, the mean diameter of tumors was 3.95 cm
(0.4–25 cm): 38.6% were smaller than 2 cm in diameter,
29.7% ranging from 2 to 4 cm, and 31.7% larger than
4 cm. Immunohistochemistry staining determined a
69.1% positive rate of CgA and a 90.2% positive rate of
Syn. Ki-67 index and mitotic rate were assessed in
127 and 118 specimens to estimate the proliferative
activities. Over half (51.5%) of the tumors were G1,
18.3% were at G2 and 30.2% at G3. The most common
tumor type was NET (69.8%), followed by NEC (27.2%)
and MANEC (3.0%). Approximately half of the assessed
tumors (53/100, 53.0%) originated from gastrointestinal
tract and biliary system with muscularis or serosaTable 2 Characteristics of imaging studies
Imaging studies Site
Endoscopy gastrointestinal tract
Gastroscope esophagus, stomach, duodenum
Duodenoscope duodenum
Small intestinal endoscope jejunum/ileum
Colonoscope rectum, appendix
Ultrasound pancreas, liver, gallbladder, cho- ledoch
EUS pancreas, duodenum, stomach
CT scan pancreas, liver, stomach
MRI pancreas, duodenum, biliary
PET-CT pancreas, rectum
EUS, endoscopic ultrasonography; CT, computed tomography; MRI, magnatic resonainfiltration at diagnosis. Local infiltration and lymphatic
metastasis occurred in 23.0% and 27.0% of patients re-
spectively. Distant metastasis was a frequent event at
diagnosis with an occurrence of 23.0% (41/178), which
increased to 28.1% (55/178) during follow up. The
liver was one of most frequently involved organs: liver
metastasis occurred in 44 (80.0%) of 55 patients in
the disease courses. Among the 44 patients, 29 pre-
sented with synchronous liver metastasis, whereas other
15 presented with metachronous liver metastasis during
follow-up. Other locations that tumors involved were the
peritoneum (12.7%, 7/55), cavitas pelvis (9.1%, 5/55),
bone (7.3%, 4/55) and ovary (5.5%, 3/55). The most com-





ulcer type, bulge type, invasive type 34 34 100
bulge type 3 3 100
small intestinal hemorrhage 2 1 50.0
polypoid prominences, submucosal uplift,
cauliflower-like neoplasm
36 36 100
hypoechoic masses, well delimited and
vascularized
63 49 77.8
hypoechoic masses 37 34 91.9
local space-occupying lesions 123 98 91.9
local space-occupying lesions 20 19 95.0
local space-occupying lesions 20 19 95.0
nce imaging; PET-CT, positron emission computed tomography imaging.
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jejunum/ileum (75.0%), gallbladder (50.0%), duodenum
(38.5%), Vater’s ampulla (33.3%) and stomach (28.0%)
(Table 3).
Therapeutic interventions
85.4% patients underwent a surgery with curative intent
(75.9%) or for palliative purpose (9.6%). Different types
of endoscopic radical surgery were performed, including
endoscopic mucosa resection (EMR), endoscopic sub-
mucosal dissection (ESD) and endoscopic electroexcision.
Local-regional therapies such as transcatheter hepatic
arterial chemoembolization (TACE), radiofrequency or
other ablative techniques were carried out only in
11 cases (6.2% of the population). Chemotherapy and
biological therapy were performed in 31 patients, among
which 15 received chemo regimen, 8 received biological
therapy and 8 received both. The most common first-
line chemo combinations included platinum-etoposide
(6 patients, 3.4%), oxaliplatin- capecitabine (2 patients,
1.3%), oxaliplatin-TS-1 (2 patients, 1.3%) and so on.
Octreotide, a somatostatin analogue, was frequently admi-
nistered at a dose of 20–40 mg/month as a biological
therapy, combined with chemotherapy in 1 patient
(0.6%) after surgery and in 7 patients (3.9%) with unre-
sectable tumors. 14 (7.9%) cases with progressive malig-






CgA 149 103 69.1
Syn 143 129 90.2
Tumor grading
G1 169 87 51.5
G2 169 31 18.3
G3 169 51 30.2
Tumor type
NET 169 118 69.8
NEC 169 46 27.2
MANEC 169 5 3.0
Infiltration/Metastasis
Muscularis/Serosa infiltration 100 53 53.0
Adjacent tissue/Capsule infiltration 178 41 23.0
Lymphatic metastasis 178 48 27.0
Distant metastasis
At initial diagnosis 178 41 23.0
During follow-up 178 55 28.1
CgA, Chromogranin A; Syn, Synaptophysin;NET, neuroendocrine tumor; NEC,
neuroendocrine carcinoma; MANEC, mixed adenoendocrine carcinoma.Survival and prognostic factors
136 out of 178 patients received long-term follow up
with a median duration of 8.6 years (range 0.03–
13.48 years). Median survival was not obtained during
the observation period. The 1-, 3- and 5-year survival
rates was 74.4%, 66.7% and 54.5% respectively, and
25 patients had died at the last follow-up (14.0%). The
major causes of death were tumor-related complications
(84.0%), and treatment-related adverse events (12.0%);
other disease contributed the other 4.0%. An analysis
was performed on patients’ age, gender, primary tumor
site, histopathological grading, classification and con-
dition of metastasis to identify prognostic factors for
survival. Univariate analysis confirmed that functional
tumors, patients were at G1 phase and classified as NET
were superior to other types of NENs in survival. Distant
metastasis also contributed to the prognosis of these
neuroendocrine tumors. However, age, sex, primary
tumor site had little impact on overall survival. The mean
survival time and statistic data were provided in Table 4.
Survival curves were displayed in Figure 1.
Discussion
The WHO classification system of gastroenteropancreatic
neuroendocrine tumors was adopted in previous studies
[3,7,8,10-12,14]. Some of these studies only focused on
particular types of GEP-NENs such as well-differentiated
endocrine tumors, poorly differentiated endocrine car-
cinomas or a single site of tumors (pancreas, colon or
rectum). Our study investigated the pathologic features
of GEP-NENs by using the latest histopathologic diagnosis
consensus for the first time. It also analyzed any possible
tumor site of digestive system including pancreas, biliary
and peritoneal cavity. This study should contribute to
establishing a database of the epidemiology, clinical patho-
logical features, treatment and prognosis of GEP-NENs in
China.
It is confirmed in our study that GEP-NENs com-
prise a heterogeneous group in relation to their pri-
mary locations. Previous researches indicated that the
small intestine and appendix were the most predominant
NENs locations [2,15-17]. But according to our study,
pancreas is the principal site of GEP-NENs. The rectum
is the most frequent sites of gastrointestinal tract, fol-
lowed by the stomach and duodenum, whereas the
jejunum/ileum accounts for no more than 2% tumor
cases. A similar distribution of NENs was also found
from a Korean study [10], which observed that rectum
was the most common primary site of tumor in 470 avail-
able cases, followed by the pancreas, stomach and duo-
denum. Results from another three registries including
SEER, National Cancer Registry for Gastroenteropan-
creatic Neuroendocrine Tumors (RGETNE, http://www.
retegep.net) and Norwegian Registry of Cancer (NRC)




95% CI χ2 P
All patients 136 9.5 8.1-11.0
Sex 2.053 0.152
Female 54 9.9 8.5-11.3
Male 82 8.7 6.7-10.6
Age 0.259 0.611
≤50 60 9.9 8.0-11.8





Pancreas 46 11.1 9.3-12.9
Functional status 6.691 0.006
Functional 22 NR NC
Nonfunctional 114 7.7 6.1-9.2
Tumor grading 9.087 0.011
G1 63 10.8 8.7-12.9
G2 25 3.5 2.6-4.3
G3 41 4.1 2.8-5.4
Tumor type 6.634 0.010
NET 88 10.1 8.1-12.1
NEC + MANEC 41 4.1 2.8-5.4
Distant metastasis 23.773 0.000
Yes 44 5.0 2.7-7.3
No 92 11.0 9.2-12.8
CI, confidence interval; NR, not reached; NC, not computable; NET,
neuroendocrine tumor; NEC, neuroendocrine carcinoma; MANEC, mixed
adenoendocrine carcinoma.
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jejunum/ileum were the most common sites for NENs
in the SEER Program tumor registry, pancreas NENs
were only the third most common NENs; The pancreas
and jejunum/ileum were the most frequent positions in
RGETNE; whereas the small intestine was the most fre-
quent sites of origin, followed by the colon and rectum
in NRC. These inconsistencies may be due to the racial
disparities, as well as the selection bias among popula-
tion based data and hospital series. So a larger patient
population is required to carry on further investigation.
NENs can be classified into functional and non-
functional tumors according to the presence or absence
of symptoms associated with hormones overproduction
[18]. The current study demonstrated that the majority
of nonfunctional NENs usually presented with non-
specific symptoms, which may give rise to misdiagnosis
of the tumors as irritable bowel syndrome or digestive
adenocarcinomas. Our study also showed that insulinomaswere the most frequently encountered functional tumors
in the pancreas, accounting for 93.1% of pancreatic
NENs. No case, however, presented with carcinoid syn-
drome in this study. Interestingly, the incidence of car-
cinoid syndrome (10–32%) in the Western population
[8,17,19-21] is significantly different from our report,
with the fact that ileal tumors account for the vast
majority.
Assessments of the locations and extents of GEP-NENs
were crucial for management. The present study ana-
lyzed imaging methods, which is commonly used in
current clinical practice, in this patient population. Con-
ventional imaging procedures include endoscopy, ultra-
sound, EUS, CT scan, MRI and PET-CT, with detection
rates ranging from 77.8 to 98.7%. CT scan was one of the
most widely used imaging modalities (123/178) whereas
endoscopy promised the highest yields of tumor detection
(98.7%). The introduction of EUS provides unique advan-
tages in evaluating the pancreatic biliary system, especially
in tumors <1.0 cm in diameter and micrometastasis. The
typical EUS patterns of NENs includes rounded, homoge-
neous, hypoechoic, well defined and vascularized masses,
with the detection rate of 91.9% in our study, rather com-
parable to the results achieved in other series [22-24].
Small tumors and liver metastasis (i.e., tumors <0.5 cm
in diameter) may be missed, resulting in underestimate
of the exact disease extent. No single technique is 100%
sensitive and accurate. Therefore, multiple imaging mo-
dalities should be combined to detect small, biochem-
ically diagnosed tumors.
Despite the advances in both morphology and biology,
the classification of NENs is still under debate. The lack
of a uniform classification system for NENs hampers
evaluation of therapy and comparison between clinical
trials [25]. European Neuroendocrine Tumor Society
(ENETS) and the North American Neuroendocrine
Tumor Society (NANETS) have published diagnosis
standard and pathology reports of NENs in 2009 and
2010 [18,26], respectively. Furthermore, the WHO revised
the nomenclature and classification of GEP-NENs in 2010,
version 4 [4]. In 2011, China established her own classi-
fication system for NENs [5]. Chinese Pathologic Con-
sensus Group suggested the term “Neuroendocrine
neoplasm (NEN)” instead of “Neuroendocrine Tumor
(NET)” and formulated the classification criteria by the
use of Ki-67 index/mitotic rate and histology. The patho-
logic features of NENs in our hospital were reviewed
according to this diagnosis consensus in the current
analysis, which to our knowledge, is the first study using
the newest consensus. Overall, G1 tumors accounted for
51.5% of 169 available cases, followed by G3 (30.2%) and
G2 (18.3%). The occurence of NET, NEC and MANEC
were 69.8%, 27.2% and 3.0%, respectively. The avail-
ability of this uniform system for NETs greatly facilitates
Figure 1 Overall survival (A) Overall survival in all patients. (B) Overall survival by sex. (C) Overall survival by age at diagnosis. (D) Overall
survival by site of tumors. (E) Overall survival by functional status. (F) Overall survival by histological grading. (G) Overall survival by tumor type.
(H) Overall survival by condition of distant metastasis.
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comparison of clinical trials.
In our series, distant disease at initial diagnosis oc-
curred at the rate of 23.0%, which increased to 28.1%
during follow up. Liver was the most frequent site tumor
involved and the distribution of distant metastasis was
wider than that either in SEER or in NRC (18–22%). In
RGETNE, however, a significant proportion of patients
(44%) with widespread disease were reported compared
with our series. The frequency of primary tumor sites
associated with distant disease varied in different series:
in our cohort, the most common sites was cecum
(100.0%), followed by jejunum/ileum (75.0%), gallbladder
(50.0%), duodenum (38.5%), Vater’s ampulla (33.3%) and
stomach (28.0%); in the SEER Registry, the most com-
mon site was pancreas (64%), followed by cecum/colon
(44%/32%) and jejunum/ileum (30%); and in the RGETNE
Registry, it was jejunum/ileum (65%), followed by colon
(48%) and rectum (40%). Therefore, jejunum/ileum
tumors appear to have a greater propensity for distant
metastasis. However, the diversity should be taken into
account.
Among the many therapeutic options for NENs, sur-
gery is the treatment of choice. A variety of operations
are available to reduce load of tumor and improve sur-
vival. The extent of surgical resection depends on the
tumor size and origin and approximately 75.9% of patients
have undergone a radical surgery. Radiofrequency ablation
or TACE is usually adopted to treat liver involvement,
accounting for 6.2% of the cases.
Besides surgery, other therapeutic options such as
chemotherapy, biological therapy and targeted therapy
can be used for NENs. According to the new WHO
2010 classification, well-differentiated NENs are classified
as G1 and G2 neuroendocrine tumors (NETs) and poor-
differentiated NENs are referred to as G3 neuroendocrine
carcinomas (NECs). It has been reported that existing
cytotoxic chemotherapy agents have been of limited
value for the treatment of well-differentiated gastrointes-
tinal NENs (with response rates 10% ~ 15%) [27-29], but
has been the standard of care for well-differentiated
metastatic pancreatic endocrine tumors (with response
rates 40% ~ 70%) [30-32]. However, chemotherapy is
generally considered active in poor-differentiated NENs
(with response rates 50% ~ 70%) [33-35]. According
to the published documents, several chemotherapeutic
regimens are available, most of them are either plat-
inum based or flurouracil based [29,34,36,37]. For the
GEP-NEC, platinum-based combination regimens with
etoposide or paclitaxel [33,34,36] are recommended. In
our cohort, chemotherapy was performed in 23 patients.
The most frequently used chemo regimen was etopo-
side–platinum combination. During follow-up, 3 of them
died of tumor progression. It has been noticed thatbiological therapy and targeted therapy promise some
effect on NENs in recent years [38-43]. Somatostatin
analogues are effective therapeutic option for functional
neuroendocrine tumors because they reduce hormone-
related symptoms [44-46]. They have also been shown
to stabilize tumor growth over long periods, even to in-
hibit tumor growth in patients with well-differentiated
metastatic neuroendocrine midgut tumors [40,47,48].
Although the treatment effect of somatostatin analogues
on foregut and hindgut tumors remain to be confirmed,
16 patients including 2 patients with functional neuroen-
docrine tumors and 14 patients with well-differentiated
metastatic GEP-NENs received long-term administration
of octreotide LAR at a dose of 20–40 mg monthly in our
study.
The prognosis of GEP-NENs is more favorable than
that of the adenocarcinomas of the digestive system. The
overall 5-year survival rate in our series was 54.5%,
rather comparable to that of SEER or NRC registry
[2,3,6] (50–59%), but it was lower than that in some
European countries [7,9] (75–79%). The inconsistencies
of survival rates may be due to the racial and geograph-
ical disparities. We also proved that prognosis differed
statistically according to functional status, pathological
grading and classification. As the great majority of func-
tional tumors were insulinomas which are benign in
most cases in our study, that may lead to the conclusion
that functionality may be a favorable prognostic marker.
The result obtained above may be caused by small
sample in this series. We also confirmed that metastasis
represented a worse outcome with a mean survival of
5.0 years (P = 0.000). Multivariate analysis was not
done due to the small size of our series. Therefore,
further evaluation in a larger patient population is
required to estimate the independent prognostic factors
of GEP-NENs.
A broad range of this heterogeneous tumors was
reviewed in the current study, which to our knowledge,
is the first report using the latest pathological diagnosis
consensus of these tumors. We also confirmed that
GEP-NENs may originate from any part of the digestive
system, and the majority of them are nonfunctional
tumors with non-specific symptoms. Endoscopy and
radiographic examination play an important role in
tumor detection. However, final diagnosis should be
based on pathological detection. The prognosis of these
tumors was more favorable compared with gastrointes-
tinal carcinomas. Nonetheless, the outcome was ex-
tremely poor for patients with high grading tumor and
distant metastasis. Further understanding of the molecu-
lar mechanisms should facilitate management of the dis-
ease. Early diagnosis is crucial for radical resection before
development of local invasion or distant disease, and
interdisciplinary cooperation is the direction of future.
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Nonfunctional tumors with non-specific symptoms ac-
count for the majority of GEP-NENs. Diagnosis depends
on pathological classification. Multidisciplinary treat-
ments could help improve the outcome.
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